Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, and Wacker Biotech announced today that they had signed a contract for the manufacturing of Prokarium’s microbial novel immunotherapy for bladder cancer.
CureVac N.V., a company based in Tübingen, Germany, needs less production capacity for CVnCOV, its mRNA vaccine candidate against Covid-19.
Wacker Chemie AG and the Finsterwalder Corporate Group intend to significantly expand their collaboration.
Wacker Chemie AG closed Q2 2021 with significant increases in both sales and earnings.
As of the end of today’s Annual Share¬holders’ Meeting, Rudolf Staudigl (66), President and CEO of Wacker Chemie AG, retired from the company. As already announced, he was succeeded in that position by Christian Hartel (50).